Clinical trials: Cardiomyopathy Due to Anthracyclines
Cardiomyopathy Due to Drug
Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity
This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment
- Trial name
- NCT06331806
- Testing
- Evaluation of myocardial fibrosis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- European Institute of Oncology
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
This phase II trial compares two drug therapy plans for the correction of heart function changes (reduced ejection function) in patients who have undergone anthracycline-based treatment for lymphoma, sarcoma, or breast cancer.
- Conditions
- Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Sarcoma
- Trial name
- NCT04190433
- Testing
- Carvedilol, Lisinopril, Pravastatin
- Sponsor
- Mayo Clinic
Cardiomyopathy Due to Drug, Heart Failure, Systolic
Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.
The intent of the study is to show the potential benefits of angiotensin converting enzyme inhibitors in preventing anthracycline induced cardiotoxicity.
- Trial name
- NCT03392740
- Testing
- Lisinopril
- Where
- United States
- Sponsor
- Ascension Health